Literature DB >> 16608842

Absence of dysferlin alters myogenin expression and delays human muscle differentiation "in vitro".

Noemí de Luna1, Eduard Gallardo, Mario Soriano, Raúl Dominguez-Perles, Carolina de la Torre, Ricardo Rojas-García, Jose M García-Verdugo, Isabel Illa.   

Abstract

Mutations in dysferlin cause a type of muscular dystrophy known as dysferlinopathy. Dysferlin may be involved in muscle repair and differentiation. We compared normal human skeletal muscle cultures expressing dysferlin with muscle cultures from dysferlinopathy patients. We quantified the fusion index of myoblasts as a measure of muscle development and conducted optic and electronic microscopy, immunofluorescence, Western blot, flow cytometry, and real-time PCR at different developmental stages. Short interference RNA was used to corroborate the results obtained in dysferlin-deficient cultures. A luciferase reporter assay was performed to study myogenin activity in dysferlin-deficient cultures. Myoblasts fusion was consistently delayed as compared with controls whereas the proliferation rate did not change. Electron microscopy showed that control cultured cells at 10 days were fusiform, whereas dysferlin-deficient cells were star-shaped and large. After 15 days the normal multinucleated appearance and structured myofibrils were not present in dysferlin-deficient cells. Strikingly, myogenin was not detected in myotubes from dysferlin-deficient cultures using Western blot, and mRNA analysis showed low levels (p < 0.05) compared with controls. Flow cytometry and immunofluorescence also showed reduced levels of myogenin in dysferlin-deficient cultures. When the dysferlin gene was knocked down ( approximately 80%), myogenin mRNA leveled down to approximately 70%. MyoD and desmin mRNA levels in controls and dysferlin-deficient cultures were similar. The reporter luciferase assay demonstrated a low myogenin activity in dysferlin-deficient cultures. These results point to a functional link between dysferlin and myogenin, and both proteins may share a new signaling pathway involved in differentiation of skeletal muscle in vitro.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16608842     DOI: 10.1074/jbc.M601885200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  40 in total

1.  Fam65b is important for formation of the HDAC6-dysferlin protein complex during myogenic cell differentiation.

Authors:  Anuradha Balasubramanian; Genri Kawahara; Vandana A Gupta; Anete Rozkalne; Ariane Beauvais; Louis M Kunkel; Emanuela Gussoni
Journal:  FASEB J       Date:  2014-03-31       Impact factor: 5.191

2.  Proteasomal inhibition restores biological function of mis-sense mutated dysferlin in patient-derived muscle cells.

Authors:  Bilal A Azakir; Sabrina Di Fulvio; Jochen Kinter; Michael Sinnreich
Journal:  J Biol Chem       Date:  2012-02-08       Impact factor: 5.157

3.  Identification and characterisation of human dysferlin transcript variants: implications for dysferlin mutational screening and isoforms.

Authors:  Zacharias Aloysius Dwi Pramono; Chin Lai Tan; Irene Ai Lian Seah; Joseph Shean Long See; Siok Yuen Kam; Poh San Lai; Woon Chee Yee
Journal:  Hum Genet       Date:  2009-02-17       Impact factor: 4.132

Review 4.  Ferlin proteins in myoblast fusion and muscle growth.

Authors:  Avery D Posey; Alexis Demonbreun; Elizabeth M McNally
Journal:  Curr Top Dev Biol       Date:  2011       Impact factor: 4.897

5.  Treatment with Recombinant Human MG53 Protein Increases Membrane Integrity in a Mouse Model of Limb Girdle Muscular Dystrophy 2B.

Authors:  Liubov V Gushchina; Sayak Bhattacharya; Kevin E McElhanon; Jin Hyuk Choi; Heather Manring; Eric X Beck; Jenna Alloush; Noah Weisleder
Journal:  Mol Ther       Date:  2017-07-03       Impact factor: 11.454

6.  Dexamethasone induces dysferlin in myoblasts and enhances their myogenic differentiation.

Authors:  Joseph J Belanto; Silvia V Diaz-Perez; Clara E Magyar; Michele M Maxwell; Yasemin Yilmaz; Kasey Topp; Guney Boso; Catriona H Jamieson; Nicholas A Cacalano; Christina A M Jamieson
Journal:  Neuromuscul Disord       Date:  2010-01-18       Impact factor: 4.296

7.  Mutations of the FHL1 gene cause Emery-Dreifuss muscular dystrophy.

Authors:  Lucie Gueneau; Anne T Bertrand; Jean-Philippe Jais; Mustafa A Salih; Tanya Stojkovic; Manfred Wehnert; Maria Hoeltzenbein; Simone Spuler; Shinji Saitoh; Annie Verschueren; Christine Tranchant; Maud Beuvin; Emmanuelle Lacene; Norma B Romero; Simon Heath; Diana Zelenika; Thomas Voit; Bruno Eymard; Rabah Ben Yaou; Gisèle Bonne
Journal:  Am J Hum Genet       Date:  2009-08-27       Impact factor: 11.025

8.  Bone marrow transplantation in dysferlin-deficient mice results in a mild functional improvement.

Authors:  Bàrbara Flix; Xavier Suárez-Calvet; Jordi Díaz-Manera; Eva Santos-Nogueira; Renzo Mancuso; Jordi Barquinero; Miquel Navas; Xavier Navarro; Isabel Illa; Eduard Gallardo
Journal:  Stem Cells Dev       Date:  2013-07-26       Impact factor: 3.272

9.  Attenuated muscle regeneration is a key factor in dysferlin-deficient muscular dystrophy.

Authors:  Yen-Hui Chiu; Mark A Hornsey; Lars Klinge; Louise H Jørgensen; Steven H Laval; Richard Charlton; Rita Barresi; Volker Straub; Hanns Lochmüller; Kate Bushby
Journal:  Hum Mol Genet       Date:  2009-03-13       Impact factor: 6.150

10.  New aspects on patients affected by dysferlin deficient muscular dystrophy.

Authors:  Lars Klinge; Ahmed Aboumousa; Michelle Eagle; Judith Hudson; Anna Sarkozy; Gianluca Vita; Richard Charlton; Mark Roberts; Volker Straub; Rita Barresi; Hanns Lochmüller; Kate Bushby
Journal:  J Neurol Neurosurg Psychiatry       Date:  2009-06-14       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.